Month: January 2015

The Japan Prize 2015 goes to Theodore Friedmann (USDA San Diego), Alain Fischer (Collège de France, Imagine Institute) and Yutaka Takahashi (University of Tokyo)

Theodore Friedmann is credited with originating the concept of gene therapy in the 1970ies and doing fundamental research since in this field. Alain Fischer demonstrated the clinical efficacy of gene therapy for the first time, using blood stem cells to treat a fatal genetic disorder called X-linked severe combined immunodeficiency. Yutaka Takahashi, a professor emeritus […]

Eiken Chemical Co. introduces point-of-care genetic testing analyzer, 6 – 96 samples, 30 min to results including DNA extraction

The system is based on a proprietary „loop-mediated isothermal amplification“ procedure (LAMP) located on a chip. Diagnostic targets are multiple respiratory infections caused by microorganisms, various infectious diseases, companion diagnostic tests and the development of various cancer-related test chips. Eiken press release, Jan. 27, 2015

Shimadzu Co. launches Nexera UC, a completely automated supercritical fluid extraction and chromatography system

The new equipment, which will be introduced at PittCon 2015, allows for the simultaneous automatized extraction and analysis of up to 48 samples. 500 different types of pesticides were detected in < 1 hr using this system. The equipment was developed jointly with Osaka University and others. Shimadzu press release, Jan. 27, 2015

3D-Matrix takes license from MIT for improved method of self-assembling peptide preparations

3D-Matrix holds a license from MIT for the production of PuraMatrixTM, a hydrogel composed of repeating units of arg-ala-asp-ala in aqueous solution. The peptide self-assembles into nanofibers on a scale similar to the extracellular matrix when exposed to physiological salt concentrations, forming a flowable hydrogel. 3D-Matrix reports to have taken another license from MIT which […]

Shonan Kamakura General Hospital starts offering plastic surgery based on autologous adipose-tissue derived mesenchymal progenitor cells

After over one year clinical studies on several female cancer patients with breast surgery, the method was classified into risk-group III (lowest risk), and a review committee was established which surveys the selection of patients and the process of therapy, according to Japanese regulations. Nikkei Biotech news release, Jan 26, 2015

Scroll to top